Science News | Researchers Identify Unique Genetic Variants to Overcome Cancer Treatment Barriers

Get latest articles and stories on Science at LatestLY. University of California, Los Angeles researchers add monoclonal antibody to target oropharyngeal cancer in HPV-positive patients with KRAS gene variant.

Representative Image

Washington [US], October 27 (ANI): University of California, Los Angeles researchers add monoclonal antibody to target oropharyngeal cancer in HPV-positive patients with KRAS gene variant.

This research represents current and future efforts to identify patients uniquely sensitive to innovative targeted treatments.

Also Read | IIM CAT Admit Card 2021 Released, Candidates Can Download Their Admit Cards Online at iimcat.ac.in.

The research builds on studies led by Dr Joanne Weidhaas at UCLA Jonsson Comprehensive Cancer Center, who found that about 16 per cent of head and neck cancer patients have inherited a variant KRAS gene. When these patients receive standard chemoradiation treatments for their HPV-positive squamous cell cancers of the oropharynx, they have both worse toxicity and worse rates of cancer control, Chin said. However, these poor outcomes may be reversed with the addition of a short course of cetuximab.

"In standard clinical practice, tumours are assumed to be different, but patients mostly uniform," Chin said. "Thus, we spent a lot of energy analysing tumours. However, we have since come to understand that our body's own immune system is crucial in making treatments effective. Matching the right body to the right treatment may make our treatments less toxic and more effective."

Also Read | Juventus vs Sassuolo, Serie A 2021-22 Free Live Streaming Online & Match Time in India: How To Watch Italian League Match Live Telecast on TV & Football Score Updates in IST?.

Chin said UCLA researchers are conducting a clinical trial in which patients with this unique combination - having both the KRAS-variant and HPV-positive squamous cell oropharyngeal cancer - are randomised to either standard of care treatment or standard of care plus cetuximab. "We think this approach of identifying unique clusters of patients may be a way for us to design new treatments that are more personalised and effective," he said. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)

Share Now

Share Now